{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:06:39Z","timestamp":1794351999987,"version":"4.9.0"},"reference-count":20,"publisher":"National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)","issue":"1","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. oncol."],"abstract":"<jats:p>Background. Breast cancer (BC) heterogeneity signifi antly complicates diagnosis, prognosis, and prediction of treatment response. MicroRNAs (miRNAs) have emerged as promising biomarkers due to their involvement in tu- mor progression and in regulating therapy sensitivity. however, the combined clinical signifi ance of circulating and tumor-associated miRNAs, such as hsa-miR-26b-5p and hsa-miR-186-5p, remains insuffi\u00a0\u00a0 \u00a0tly elucidated. Materi- als and Methods. Expression levels of hsa-miR-26b-5p and hsa-miR-186-5p were analyzed in serum and tumor tis- sue of 124 BC patients. Associations with clinicopathological parameters were assessed. The prognostic signifi ance was evaluated based on disease progression and recurrence within 3 years. The predictive value was determined in patients receiving neoadjuvant chemotherapy (4AC regimen) using response assessment and ROC analysis. Re- sults. young BC patients (\u226445 years) demonstrated signifi antly lower circulating levels of both miRNAs. Serum hsa-miR-186-5p expression was associated with early-stage disease, tumor size, lymph node status, and molecular subtype. Increased circulating hsa-miR-26b-5p levels were linked to disease progression, whereas decreased hsa- miR-186-5p levels were observed in patients with unfavorable outcomes. In tumor tissue, hsa-miR-26b-5p expres- sion correlated with tumor grade, size, and metastatic status, showing elevated levels in poorly differentiated tumors and reduced expression in metastatic disease. In contrast, hsa-miR-186-5p was associated with the molecular sub- type and lymph node involvement, with the highest expression observed in hER2-positive tumors and in patients with recurrence. Elevated levels of hsa-miR-186-5p in both serum and tumor tissue were associated with reduced sensitivity to doxorubicin-based neoadjuvant chemotherapy. ROC analysis confi med its predictive value (AUC = \u00a00.750 for serum and 0.818 for tumor tissue). No signifi ant association between hsa-miR-26b-5p and chemothe- rapy response was observed. Conclusions. hsa-miR-26b-5p and hsa-miR-186-5p demonstrate complementary roles in BC biology. hsa-miR-26b-5p is primarily associated with tumor aggressiveness and cancer progression, whereas hsa-miR-186-5p refl cts its molecular characteristics and response to chemotherapy. Their combined assessment in serum and tumor tissue represents a promising approach for improving prognostic stratifi ation and predicting treatment effi acy in BC patients.<\/jats:p>","DOI":"10.15407\/exp-oncology.2026.01.031","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:31:09Z","timestamp":1781519469000},"page":"31-39","source":"Crossref","is-referenced-by-count":1,"title":["Integrated Analysis of hsa-miR-26b-5p and hsa-miR-186-5p in Blood Serum and Tumor Tissue Reveals their Prognostic and Predictive Significance in Breast Cancer"],"prefix":"10.15407","volume":"48","author":[{"given":"\u041e.","family":"Martyniuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mushii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"32237","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"17568","doi-asserted-by":"crossref","unstructured":"Guo L, Kong D, Liu J, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12(1):3. https:\/\/doi.org\/10.1186\/s40164-022-00363-1","DOI":"10.1186\/s40164-022-00363-1"},{"key":"17569","doi-asserted-by":"crossref","unstructured":"Sinha SJ, Kumar B, Prasad CP, et al. Emerging research and future directions on doxorubicin: A snapshot. Asian Pac J Cancer Prev. 2025;26(1):5-15. https:\/\/doi.org\/10.31557\/APJCP.2025.26.1.5","DOI":"10.31557\/APJCP.2025.26.1.5"},{"key":"17570","doi-asserted-by":"crossref","unstructured":"Jelski W, Okrasinska S, Mroczko B. MicroRNAs as biomarkers of breast cancer. Int J Mol Sci. 2025;26(9):4395. https:\/\/doi.org\/10.3390\/ijms26094395","DOI":"10.3390\/ijms26094395"},{"key":"17571","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz JP, P\u00e9rez-Moreno P, P\u00e9rez Y, et al. The role of microRNAs in breast cancer and the challenges of their clinical application. Diagnostics (Basel). 2023;13(19):3072. https:\/\/doi.org\/10.3390\/diagnostics13193072","DOI":"10.3390\/diagnostics13193072"},{"key":"17572","doi-asserted-by":"crossref","unstructured":"Zhao H, Wang B, Yang L, et al. miRNA-186-5p inhibits migration, invasion and proliferation of breast cancer cells by targeting SBEM. Aging (Albany NY). 2023;15(14):6993-7007. https:\/\/doi.org\/10.18632\/aging.204887","DOI":"10.18632\/aging.204887"},{"key":"17573","doi-asserted-by":"crossref","unstructured":"Wang Z, Zhou X, Deng X, et al. miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer. Front Oncol. 2023;13:1166666. https:\/\/doi.org\/10.3389\/fonc.2023.1166666","DOI":"10.3389\/fonc.2023.1166666"},{"key":"17574","doi-asserted-by":"crossref","unstructured":"Wilke CM, Hess J, Klymenko SV, et al. Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer. Int J Cancer. 2018;142(3):573-583. https:\/\/doi.org\/10.1002\/ijc.31072","DOI":"10.1002\/ijc.31072"},{"key":"17575","doi-asserted-by":"crossref","unstructured":"Chekhun V, Borikun T, Mushii O, et al. Expression profile of miR-145, -182, -21, -27a, -29b, and -34a in breast cancer patients of young age. Exp Oncol. 2024;45(4):421-431. https:\/\/doi.org\/10.15407\/exp-oncology.2023.04.421","DOI":"10.15407\/exp-oncology.2023.04.421"},{"key":"17576","doi-asserted-by":"crossref","unstructured":"Borikun T, Mushii O, Pavlova A, et al. Tumor microenvironment-associated miR-7-5p, miR-19a-3p, and miR-23b-3p expression in prostate cancer with different progression risk. Exp Oncol. 2024;45(4):432-442. https:\/\/doi.org\/10.15407\/exp-oncology.2023.04.432","DOI":"10.15407\/exp-oncology.2023.04.432"},{"key":"17577","doi-asserted-by":"crossref","unstructured":"Martyniuk O, Mushii O, Chekhun V. Role of miR-26b-5p and miR-186-5p in breast cancer patients of young age: Clinical associations and relation to anthracycline response. Exp Oncol. 2026;47(4):459-466. https:\/\/doi.org\/10.15407\/exp-oncology.2025.04.459","DOI":"10.15407\/exp-oncology.2025.04.459"},{"key":"17578","doi-asserted-by":"crossref","unstructured":"Chekhun V, Borikun T, Zadvornyi T, et al. Osteonectin (SPARC) prognostic value in prostate cancer. Pathol Res Pract. 2024;254:155053. https:\/\/doi.org\/10.1016\/j.prp.2023.155053","DOI":"10.1016\/j.prp.2023.155053"},{"key":"17579","doi-asserted-by":"crossref","unstructured":"Jing S, Tian J, Zhang Y, et al. Identification of a new pseudogenes\/lncRNAs-hsa-miR-26b-5p-COL12A1 competing endogenous RNA network associated with prognosis of pancreatic cancer using bioinformatics analysis. Aging (Albany NY). 2020;12:19107-19128. https:\/\/doi.org\/10.18632\/aging.103709","DOI":"10.18632\/aging.103709"},{"key":"17580","doi-asserted-by":"crossref","unstructured":"Cui XW, Qian ZL, Li C, Cui SC. Identification of miRNA and mRNA expression profiles by PCR microarray in hepatitis B virus associated hepatocellular carcinoma. Mol Med Rep. 2018;18:5123-5132. https:\/\/doi.org\/10.3892\/mmr.2018.9516","DOI":"10.3892\/mmr.2018.9516"},{"key":"17581","doi-asserted-by":"crossref","unstructured":"Yu DH, Ruan XL, Huang JY, et al. Analysis of the interaction network of hub miRNAs-hub genes involved in idiopathic pulmonary fibrosis and its emerging role in non-small cell lung cancer. Front Genet. 2020;11:302. https:\/\/doi.org\/10.3389\/fgene.2020.00302","DOI":"10.3389\/fgene.2020.00302"},{"key":"17582","doi-asserted-by":"crossref","unstructured":"Ning R, Meng S, Wang L, et al. Six circulating miRNAs as non-invasive biomarkers for the detection of cervical lesions. J Cancer. 2021;12:5106-5113. https:\/\/doi.org\/10.7150\/jca.51141","DOI":"10.7150\/jca.51141"},{"key":"17583","doi-asserted-by":"crossref","unstructured":"Bayat Z, Ghaemi Z, Behmanesh M, Soltani BM. hsa-miR-186-5p regulates TGF\u03b2 signaling pathway through suppression of SMAD6 and SMAD7 genes in colorectal cancer. Biol Chem. 2021;402:469-480. https:\/\/doi.org\/10.1515\/hsz-2019-0407","DOI":"10.1515\/hsz-2019-0407"},{"key":"17584","doi-asserted-by":"crossref","unstructured":"Wu Zh, Li C, Zhang YJ, Lin R. Bioinformatics study revealed significance of exosome transcriptome in hepatocellular carcinoma diagnosis. Front Cell Dev Biol. 2022;10:813701. https:\/\/doi.org\/10.3389\/fcell.2022.813701","DOI":"10.3389\/fcell.2022.813701"},{"key":"17585","doi-asserted-by":"crossref","unstructured":"Ke Y, Zhuang X, You L. Identification of core genes shared by endometrial and ovarian cancer using an integrated approach. Cell Mol Biol (Noisy-le-grand). 2022;68:140-145. https:\/\/doi.org\/10.14715\/cmb\/2022.68.9.22","DOI":"10.14715\/cmb\/2022.68.9.22"},{"key":"17586","doi-asserted-by":"crossref","unstructured":"Zhang W, Zhang Q, Che L, et al. Biological information-based analysis of potential miRNA-mRNA regulatory networks in plasma of patients with non-small cell lung cancer. BMC Cancer. 2022;22:299. https:\/\/doi.org\/10.1186\/s12885-022-09281-1","DOI":"10.1186\/s12885-022-09281-1"},{"key":"17587","doi-asserted-by":"crossref","unstructured":"Xue J, Jia E, Ren N, Xin H. Identification of prognostic miRNA biomarkers for esophageal cancer based on TCGA and GEO datasets. Medicine (Baltimore). 2021;100:e24832. https:\/\/doi.org\/10.1097\/MD.0000000000024832","DOI":"10.1097\/MD.0000000000024832"}],"container-title":["Experimental Oncology"],"original-title":[],"link":[{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/615\/460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/615\/460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:40:35Z","timestamp":1781520035000},"score":1,"resource":{"primary":{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/view\/615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,14]]}},"URL":"https:\/\/doi.org\/10.15407\/exp-oncology.2026.01.031","relation":{},"ISSN":["2312-8852","1812-9269"],"issn-type":[{"value":"2312-8852","type":"electronic"},{"value":"1812-9269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,14]]}}}